Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation

Lung, Respiratory and Thoracic Cancer

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

Lung Cancer

Zhang Q, Yang Y, Xie M, Zhou Z, Wu H, Zhai W, Chen Y, Chen K, Zhou S, Li H, Fan Y

doi: 10.1016/j.lungcan.2025.108616

Lung, Respiratory and Thoracic Cancer

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Lung Cancer

Huijs JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, Bensch F, Hijmering-Kappelle LBM, de Schrevel TMT, van Geffen WH, Youssef-El Soud M, Steens MMH, Pitz C, De Ruysscher DKM, Hendriks LEL

doi: 10.1016/j.lungcan.2025.108745

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Lung, Respiratory and Thoracic Cancer

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study

Eur J Cancer

Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, Pichon E, Veillon R, Gounant V, Rousseau-Bussac G, Madroszyk A, Daniel C, Ravoire M, Metivier AC, Fournel P, Missy P, Morin F, Guisier F, Westeel V

doi: 10.1016/j.ejca.2025.115301

Lung, Respiratory and Thoracic Cancer

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study

Clin Cancer Res

Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR

doi: 10.1158/1078-0432.CCR-24-3658

Lung, Respiratory and Thoracic Cancer

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

Lung Cancer

Dingemans AC, Syrigos K, Livi L, Paulus A, Kim SW, Chen Y, Felip E, Griesinger F, Ohashi K, Zalcman G, Hughes BGM, Sørensen JB, Blais N, Ferreira CGM, Lindsay CR, Dziadziuszko R, Ward PJ, Obiozor CC, Wang Y, Peters S

doi: 10.1016/j.lungcan.2025.108683

Lung, Respiratory and Thoracic Cancer

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival

Lung Cancer

Eklund EA, Orgard M, Wallin D, Sayin SI, Fagman H, Isaksson J, Raghavan S, Akyürek LM, Nyman J, Wiel C, Hallqvist A, Sayin VI

doi: 10.1016/j.lungcan.2025.108573

Lung, Respiratory and Thoracic Cancer

Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes

Lung Cancer

Krayim B, Shalata W, Bar J, Moskovitz M, Rotem O, Urban D, Sorotsky HG, Kian W, Hanovich E, Marie R, Mann S, Gillis R, Basel A, Kornev G, Asna N, Peled N, Roisman LC

doi: 10.1016/j.lungcan.2025.108598

Lung, Respiratory and Thoracic Cancer

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation

Adv Ther

Chopra D, Lan Z, Waterhouse DM, Wolf J, Felip E, Moradian H, Karim N, Obiozor C, Stollenwerk B

doi: 10.1007/s12325-025-03259-8

Related content

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival

Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation